NEW YORK (GenomeWeb) – Cancer Genetics today announced an agreement to buy Indian genomics and next-generation sequencing services firm BioServe Biotechnologies for $1.9 million, primarily in stock and other deferred considerations.

The Rutherford, NJ-based cancer genetics testing firm also reported a 17 percent increase in its first quarter revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.